Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valneva Snares Pfizer For Lyme Disease Vaccine Pact

French Biotech Banks $130m Upfront

Executive Summary

Days after inking a COVID-19 collaboration with Dynavax, Valneva has linked up with Pfizer to drive its Lyme disease vaccine VLA15 towards Phase III trials.

You may also be interested in...



Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost

Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.

Coronavirus Update: New Funding For Valneva, Scotland Looks At Long COVID

France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody. 

Valneva Spies Chance To Join Third Wave Of COVID-19 Vaccines

The company is hoping for strong efficacy from its inactivated vaccine, boosted by two adjuvants

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC142149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel